NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) | Biotech Hunter

Timeline

Start Date

September 19, 2017

Primary Completion Date

October 12, 2017

Study Completion Date

October 12, 2017

Conditions

Autoimmune Diseases

Interventions

DRUG

GSK2618960 2 mg/kg

GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.

DRUG

Placebo

Placebo solution will be administered by IV infusion.

DRUG

Methotrexate

MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.

Trial Locations (1)

GSK Investigational Site, Cambridge